Several biomarkers, including high tumor mutational burden, PD-L1 and/or PD-1 expression, and the presence of tumor-infiltrating lymphocytes in the tumor microenvironment, have been extensively studied as predictors of responses to therapy2. The gene discussed is CD274; the disease is neoplasm.